The Future of Transdermal and Microneedle Drug Delivery according to Ester Caffarel-Salvador
The Future of Transdermal and Microneedle Drug Delivery according to Ester Caffarel-Salvador, Associate Director, Regenerative Medicine, LEO Pharma A/S. In preparation for the Inaugural Transdermal and Microneedle Drug Delivery Conference
By: SMi Group
Microneedle patches are a popular area of research currently, what do you believe are the most important factors to consider when designing a microneedle patch? Do you believe we should be focusing on dissolvable patches?
"There is no "one-size-fits-
Dissolvable patches pose a notable advantage compared to metal microneedles by obviating sharp waste, however, their drug loading capacity is limited. As researchers devise new ways to increase loading capacity, translating the dissolving microneedles systems to the market remains a challenge in the field because achieving consistent drug exposure levels in clinical studies has proven to be difficult. Reproducibility is key for microneedles to succeed."
What current hot topic will you be addressing in your presentation and what would you say makes it relevant to 2022?
"With the increasing number of microneedle-
For this reason, my talk will be aimed at discussing the key challenges of delivering macromolecules in the gastrointestinal tract and how the use of microneedles in oral drug delivery devices can help circumvent such challenges."
SMi Group is proud to present the inaugural Transdermal and Microneedle Drug Delivery Conference, taking place on the 24th to 25th January 2022, in London, UK. The Conference will explore real world applications of microneedles in drug delivery and strategies for device design while engaging in the latest innovations in device design and formulation with case studies from thought leaders.
Sponsors of the conference include: LTS Lohmann Therapie-Systeme AG, QuadMedicine
Transdermal and Microneedle Delivery
24-25 January 2022